

## ***Supplementary Material***

### **1.1 Supplementary Methods**

#### **Cuticle permeability assay**

Cuticle permeability to 4',6-Diamidino-2-Phenylindole (DAPI) was assessed as previously described (Xiong et al., 2017). Briefly, AT3q130 and double mutant animals were synchronized by egg-laying. At day 4, worms were washed from plates with M9 buffer before staining with DAPI (diluted in M9 buffer to a final concentration of 5 µg/mL) for 15 minutes, at 20°C, in a rotating device. After incubation with DAPI, worms were washed three times with M9 buffer. For microscopy, worms were mounted onto 3% agarose pads, and anesthetized with 10 µL of levamisole 10 mM and sealed with a coverslip and agarose on coverslip edges, before being imaged on a fluorescence microscope, Olympus Widefield Upright Microscope BX61 using 10x objective (NA 0.4). Images were captured with DP73 Olympus camera and using the CellSens software. *bus-19(e2966)* was used as a positive control (Yook and Hodgkin, 2007).

#### **Dye filling assay**

Dye filling assay in AT3q130 and double mutant animals was performed as previously described (Tong and Burglin, 2010), with the following modifications. A stock solution of 2 mg/ml DiD (1,1'-dioctadecyl-3,3,3',3'-tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate salt, Molecular Probes, catalog # D-282), in dimethyl formamide was stored at -20°C, protected with aluminum foil from the light. A working solution of DiD in M9 was prepared (1:800 dilution) fresh on the day of the assay. Worms were washed from plates with M9 buffer before incubation with the DiD working solution for 1 hour, at 20°C, in a rotation device. Then, worms were washed three times with M9 buffer and allowed to recover on plates for at least 1 hour, to try to remove ingested dye from the intestine. For microscopy, worms were mounted onto 3% agarose pads, and anesthetized with 10 µL of levamisole 10 mM and sealed with a coverslip and agarose on coverslip edges, before being imaged on a fluorescence microscope, Olympus Widefield Upright Microscope BX61 using 40x objective (NA 0.9). Images were captured with DP73 Olympus camera and using the CellSens software. *osm-6(p811)* and *xbx-1(ok279)* were used as positive controls for abnormal dye filling phenotype (Perkins et al., 1986; Schafer et al., 2003).

#### **Pharyngeal Pumping assessment**

For quantification of pharyngeal pumping, ~10 synchronized adult animals (4 days after hatching, at 20°C) were transferred to freshly seeded plates and filmed for 15-20 seconds. Animals on the borders of the bacterial lawn were selected, in order to minimize movement, and the total number of terminal bulb grinder contractions was manually counted in 0.5x speed videos. Number of pumping was calculated by averaging 31-32 worms from three independent assays, and pumping rate per minute was calculated.

## 1.2 Supplementary Figures






Figure S1

Figure S1



**Supplementary Figure S1 (related with Figure 2) – Original Western blot images presented in this study. (A)** Blot of ATXN3 levels, total protein (used for ATXN3 levels normalization), and molecular weight indications. The highlighted rectangle is shown in Fig. 2C. **(B)** Biochemical fractionation blot, depicting protein loading control and Triton X-100-soluble, SDS-soluble and SDS-resistant fractions. Total protein blot is also showed, as values presented in Fig. 2F were normalized to the total protein of the DMSO loading control. **(C)** Quantification of the filter retardation of WT, mutant ATXN3 and mutant ATXN3 strain with a deletion in *mod-5* gene showed that MOD-5 is a modifier of ATXN3 aggregation (as previously described in (Pereira-Sousa et al., 2021)). (n = 4,  $\pm$  SD) \* $p$ <0.05, (ANOVA, Dunnett T3 test) **(D)** Filter retardation assay blots. Some wells (indicated with an X) were eliminated from the analysis. This was due to an experimental constraint, specifically, clogging of the filter, which prevented the samples to pass through the membrane efficiently. The highlighted rectangle (dashed, black) is shown in Fig. 2G. **(E)** Total protein gels using the samples of the filter retardation assay. Filter retardation assay blot densitometry values were normalized to total protein staining of these gels. APZ – aripiprazole.

**Figure S2**



**Supplementary Figure S2 (related with Figure 4) – Estrone controls of the pharmacogenetics assay.** Double mutant strains, lacking a specific dopamine/serotonin receptor and expressing mutant ATXN3 proteins (AT3q130 animals), were also treated with estrone (a steroid hormone). Estrone treatment was able to ameliorate AT3q130 locomotion deficits in all double mutants (n = 3,  $\pm$  SD), \* $p$ <0.05, \*\* $p$ <0.01, \*\*\* $p$ <0.001 (Factorial ANOVA, followed by Sidak test corrected for BCA for multiple comparisons).

DRD2_HUMAN	1	MDP-----LNLSWYDDDLERQNWSRPFNGSDGKADRPHYNYATLLTLLIAVIVFGNVLV
DOP-2	1	MEAGETWNVSLEWPPPSLLSTITQTPSTIVGSC--IPINVACLSLIVITPLITLLGNLLV
DRD2_HUMAN	56	CMAVSREKALQTTTNYLIVSLAVADLLVATIVMPVWVYLEVV-GEWKFSRTHCDIFVTLQ
DOP-2	59	IISVLRYSALQSAINELILGLAVADLLVATIVMPMAVYVYVTNGDWYLGNI MCDIYMASD
DRD2_HUMAN	115	VMMCTASILNLCATSIDRYTAVAMPNLYNTRYSSKRRVTVMISIVWVISFTISCPLIFGL
DOP-2	119	VCCSTASILLLAVISFDRYRAVSLPTQYSRQSQNVRRVWTLIAVIWLVSLLTASPMVFGV
DRD2_HUMAN	175	NN----ADQNECIIANPAFVVYSSIVSFYVFFITLLVYIKIYIVLRRRRKRVNTRKRSSR
DOP-2	179	NVRPPDANPYECRFYNABESILSSMISEVTPCFIVLEFVYIRITIALKKREKAAKMRREKN
DRD2_HUMAN	231	AFRAHLR-APLKG-----N-----
DOP-2	239	TIAHGLTMRPDTGEEQVDEEAAGRIVAGPDEREFNGSSSTPRSSLESLSENVNVITNDFVS
DRD2_HUMAN	244	-----
DOP-2	299	ENCTTFSRSSSYADDSQPTSSQTSSGDGRSYSIKGQKRFRNLSRNYSTKHHRKVVKVNRG
DRD2_HUMAN	244	-----CTHPEDMKLCTVIMK-SNGSEFVNRRRVEAAR-AGEEEMELSSSTSPPER
DOP-2	359	NSRNNSRTASITNQSDDALIPAIIRPTISRKSEPLERRDKTDIKHSMILAN-PIITEPPKE
DRD2_HUMAN	293	TR-Y-SPIPPSHHQLTLP-----
DOP-2	418	YRRVSMPIHPTNSQTETETISASRDLENLPTTTISRSTTANSALLGSPDDFEKFPALIT
DRD2_HUMAN	309	-----DPSHHGLHSTPDSPAKPEKNGHAKD-----
DOP-2	478	ETVLEDVLAETREGCFMQPTVSFALTVREMEGNALNNLKGCSVESSRRVSVQVDPPLAIQI
DRD2_HUMAN	334	-----HPKIAKIFETQMPNGKTRT-SLKTMS-----
DOP-2	538	LTRPSLPFLDLQRMDSIGTTCSSKTRADSLRSVDSKGSKKSNRNGIAVKLVKRAIKHEHS
DRD2_HUMAN	360	-RRKL--SQQKEKRTATQMLAIVLGVELICWLPFFITHILNIHC-----DCNIPPVLYSA
DOP-2	598	LKRKMSKAQRKEKRTATKTLGVVVGVELVCWVPFFVINILNAVCIILNKDSCQVGYDLFFY
DRD2_HUMAN	411	FTWLGYNNSAVNPPIIYTTFNTEFRFAFLKITH-----C
DOP-2	658	CTWLGYNNSFNPPIIYTTFNTEFRFAFKSIIFGRNSTRHHFSNKQAEV

**Supplementary Figure S3 (related with Figure 3) – Total sequence alignment of human DRD2 (UniProtKB – P14416) with DOP-2 (isoform a) (UniProtKB – E7EM37-2).** Pairwise sequence alignments were obtained using Jalview 2.11.1.3 alignment service T-coffee (Notredame et al., 2000; Troshin et al., 2011).

DRD2_HUMAN	1	MDPLNLSWYDDDLERQNSRPNNGSDGKADRPHYNYATLLTLLIAVIVFGNVLVCMVAVS
DOPR3_CAEEL	1	MLAGQ--HHVTDLESPLMVVLNRVA-----AGVFLPLVPTMAVFGNVLVIMSVF
DRD2_HUMAN	61	REKALQTTTNYLIVSLAVADLVATLVMPVTVYLEVV-GEWKFSRIHCDIFVTLDVMMCT
DOPR3_CAEEL	48	REKSLQTVTNMLIVSLAVSDFMVAIGVMSEGVYYEWNDFKWGLGSFFCHVYQALDVACST
DRD2_HUMAN	120	ASILNLCAISIDRYTAVAMPMLYNTRYSSKRRVTVMISIVWVLSFTISCPLLFGLINNAD-
DOPR3_CAEEL	108	ASILNLLAISIDRYTAICHPTSYAQYGARGGRAMISITIVWGVSVAVALPLLLGVNPMEE
DRD2_HUMAN	179	--QNECTIANPAFVYSSIVSFYVPFIVTLLVYIKIYIVLRRRRKRVNTKRSSRAFRAHL
DOPR3_CAEEL	168	NDLQECETANPYENMISSIEFSFIPCIAMIILYTIIERRLRQERARSLRQAQRSENDKI
DRD2_HUMAN	237	RAPLKGNCTHPEDM-----KLCTVIMKSNGSFPPVNRRRVEAARR-----
DOPR3_CAEEL	228	SSALLGGAQIARQMGKHFKNRDQILLETISF-QTSSFPTMSESSEDASTISPMINSFNNE
DRD2_HUMAN	276	-----
DOPR3_CAEEL	287	LPKKTPYPSTSIPIAIECGSMPNLTIIERPEAEKEKEISIMDLRDTVEMLDDKYSSAILT
DRD2_HUMAN	276	-----AQELEM-----EMLSSTSPPERTRYSPIPPS-----
DOPR3_CAEEL	347	SFQTSRSFGEELFEILPFIDGSNSVKHSREQLHTTRSNSTSTRLLDVKPELRSISVPSIQ
DRD2_HUMAN	302	-----HHQLTLDPDPSHHGLHSTPDSPAKPE-----KNGH
DOPR3_CAEEL	407	DEKKLSQKSNDLPFSHQNGTHKQKLLPNPG---ILMKSSTTLLKTNGYMDTDSLNRNSH
DRD2_HUMAN	331	AKDH-----PKIAKIFEIQTMPNGKTRTSLKTMSSRRKLSQQKEKKA
DOPR3_CAEEL	464	KKSLADLLANDEFSSFSDSMRVYKNRIFKSLSRATSGWNKPRPSRHMVKKATKQMRREHKA
DRD2_HUMAN	372	TQMLAVLVGVFLICWLPPFVTHILNIHCD-----CNIPPVLYSAFTWLGYVNSAVNPI
DOPR3_CAEEL	524	TVTLAVVLAVFLFCWLPPFVHLHSNSICLIIDENSACVGFLPLYL-ATWLGYLNSSLNPL
DRD2_HUMAN		425IYTTENIEFRKAFLKILHC-----
DOPR3_CAEEL		583IYTVFDQRFNNAFRNIIISCGIFKKR

**Supplementary Figure S4 (related with Figure 3)** – Total sequence alignment of human DRD2 (UniProtKB – P14416) with DOP-3 (UniProtKB – Q6RYS9). Pairwise sequence alignments were obtained using Jalview 2.11.1.3 alignment service T-coffee (Notredame et al., 2000; Troshin et al., 2011).

5HT1A_HUMAN	1	MDVLSPGQGNNITSP---APF-ETGNT-----TGISDVTVSYQVITSL
G5EGH0_CAEEL	1	M--IDETLLNLTASPS SQPATLLSAVARGTHLVDQFPAHAEIFSDIERPLVQTVILASVL
5HT1A_HUMAN	43	LGTLLFCAVTIGNACVVAATAIERSLQNVN-NYLLIGSLAVTDLVSVLVLPMAALYQVLNK
G5EGH0_CAEEL	59	L-VLLLSCFIGNLFVLAIIEMERDLRGRPOYYLIFSLAVADLLVGMIVTPLGAWFTVTGT
5HT1A_HUMAN	102	WTLGQVTCDLFIADVLCCTSSILHLCAIALDRYWAITDPIDYVNRTPRRAAALISLTW
G5EGH0_CAEEL	118	WNLGVVVCDFWISVDLVCTASILHLVAIALDRYWSITD-ICVQNRTPKRITLMLAVIW
5HT1A_HUMAN	162	LIGFLISTPPMLGWRTP--EDRS-DPDACTISKDHGYTIYSTFGAFYIPLLLMLVLYGRI
G5EGH0_CAEEL	177	FTSLILISTAPFAGWKDEGFSRVLKSHVCLISQQISYQVFSTATAFYIPLIAIICVYWKI
5HT1A_HUMAN	219	FRAAFERIR-----KTVKKVEKTCADTRHGASPAQPKKS-----VNGES
G5EGH0_CAEEL	237	MRAAKKREKREERDRRTVIRPPDAIDKKAMM----PKKSKKCPLPPAVVISDIQANGGT
5HT1A_HUMAN	259	GSRNWRIGVESKAGGALCANGAVRQGDGAALVIEVHRVGNKEHLPLPSEAGPTPC--
G5EGH0_CAEEL	293	GGRKNSIKN-----PPRHNESS--SSASEEERTMTQTNHAPGDVTTQETKIDE
5HT1A_HUMAN	317	-----APASFERNERNAEAKRKMATARERKTVKTLGIIMGTFILCWL PFFIVALVLPFC
G5EGH0_CAEEL	339	ENGRSKPGIV----KRRRRRTKESNEMKRERKAWRTLAIITGTGFACWTPFFLVSIYRPIC
5HT1A_HUMAN	372	ESSHMPPTLLGALINWLGYSNSLLNPVIYAYFNKDFQNAFKKIICKFCRQ---
G5EGH0_CAEEL	395	G--CQSPVLEQVTLWLGYNLSALNPPIIYTVFSQDFRAAFKRIIK-RMCLIHDY


**Supplementary Figure S5 (related with Figure 3)** – Total sequence alignment of human 5-HT<sub>1A</sub> (UniProtKB – **P08908**) with SER-4 (UniProtKB – **G5EGH0**). Pairwise sequence alignments were obtained using Jalview 2.11.1.3 alignment service T-coffee (Notredame et al., 2000; Troshin et al., 2011).

5HT2A_HUMAN	1	MDILCEENTSLSSSTTNSLMQLNDTRLYSNDFNSGEAN-----TSDAFNWTVDSENR
O17470_CAEEL	1	MLIELFSHSA---PP-----EDPYV-----PANESFATTALT-----PHFSTT
5HT2A_HUMAN	53	TNLSCEGCLSPSCSLSLHLOEKNWSA-LLTAVVILITTAGNILEVIMAVSLEKKLQONATNY
O17470_CAEEL	37	SVWSIRVQLIPT-MGYHF---NGVALFLLPVLCLIGLIGNFLVCVAIATDRRLHNVNTNY
5HT2A_HUMAN	112	FLMSLAADMLLGFIVMPVSMITIIYGYRWPLPSKLCVWIIYLDVLFSTASIMHLCAISL
O17470_CAEEL	93	FLFSLAADIILVCCIVMPLSIVVEVRHGVWTSVSMCLLYVYSDVFLCSASIVHMSVISL
5HT2A_HUMAN	172	DRYVAIQNPPIHHSRFNSRTKAFKIIAVWTISVGTSMPIPVFGLQDDSKVFKEGSCLLAD
O17470_CAEEL	153	DRYLCISQPLR-TRNRSKTLIFIKIAIVWVVTLLVSCPIAVLAMHDTANILRNNQCMIFS
5HT2A_HUMAN	232	DNEVLTGSFVSFFIPLTIMVITYFLTIKSLQKEATLCVSDLGTRAKLASF-SFLPQSSLS
O17470_CAEEL	212	RYIITYGSTMTLEIPLCIMGVTYAKTTQLLNKQASILSOKAGDKFNGNGLRRTMPHRKLG
5HT2A_HUMAN	291	SEKLEQRSIHREP-----
O17470_CAEEL	272	YARTYSATVNGTIANGKAIGAHGRMTSSISNIANGETADRLGTSRPSINTNGHKQLQKAS
5HT2A_HUMAN	304	-----CSYTGRR-----TMQSSNEQKACKVLGIVFFLFVVMWCPFFIT
O17470_CAEEL	332	TINKWKSRTSNLVTNFAANKVGRRSSLOQTATQDLANEHKATRVLAUVFACFFICWTTPFFFI
5HT2A_HUMAN	343	NIMAVICKESCNEDVIGAILNVFWIGYSSAVNPLVYTLFNKTYRSAFSRYIQCYKEN
O17470_CAEEL	392	NELIGFGGEN--VQIPDWASIFLWLGYSSTINPIITYTVFNKRFRQAFVRIIRCQCFHP
5HT2A_HUMAN	403	-KKPIQL---ILVNTIPALAYKSS-----
O17470_CAEEL	450	LRDSHQMYSRNFTTTIVPDYTCRSRNOERTTSVITRDETRSARSSERPEPSRARSEISE
5HT2A_HUMAN	423	-----QLQM-----GQKKNSKQDAKTTDNDCS-----
O17470_CAEEL	510	EPVARTNCKLTSEKKKISLPSFPRVSSSRDSRATTEASTTDEETKPLIPKSTVPATVINI
5HT2A_HUMAN	445	-----MVALG-----
O17470_CAEEL	570	PEQLINPIKKSLLTTIINMPLLDETIPEKAQVHHKSQTLLTSSTLNFATFSTCPQQPTRSY
5HT2A_HUMAN	450	----KQHSEEASKDNS-----DGVNEKVS-----V
O17470_CAEEL	630	SCVDCKKAEKMLSSDVSDMMTTSTASTASTVNGAPRKHLTLFNHFDSAIKETFL

**Supplementary Figure S6 (related with Figure 3)** – Total sequence alignment of human 5-HT<sub>2A</sub> (UniProtKB – **28223**) with SER-1 (UniProtKB – **O17470**). Pairwise sequence alignments were obtained using Jalview 2.11.1.3 alignment service T-coffee (Notredame et al., 2000; Troshin et al., 2011).




Figure S7




**Supplementary Figure S7 - Permeability to DAPI of AT3q130 and double mutant animals, and DAPI fluorescence intensity measures.** (A) Representative images of DAPI permeability in AT3q130 and double mutant animals. (B) Double mutant strains, lacking a specific dopamine/serotonin receptor crossed with AT3q130, do not differ on intensity of DAPI, when compared to single mutant AT3q130 animals. Positive control for cuticle defects, *bus-19(e2966)*, is characterized by high permeability to DAPI. Scale bar represents 25  $\mu m$ . (n = 6-8,  $\pm$  SD), \*\* $p < 0.01$  (One-way ANOVA with Games-Howell Post-Hoc for multiple comparisons).


Figure S8



**Supplementary Figure S8 – Dye filling assay of AT3q130 and double mutant animals. (A)** Representative images of dye uptake in head sensory neurons of AT3q130 and double mutant animals. **(B)** AT3q130 and double mutant worms incubated with a lipophilic fluorescent dye, DiD, can uptake the dye through their sensory neuronal ciliated endings, and fluorescently mark the sensory neurons processes and cell bodies of the amphid (head) sensory neurons. This indicates that sensory neuronal endings are well formed in all strains. *osm-6(p811)* and *xbx-1(ok279)* were used as positive controls for abnormal dye filling phenotype and are unable to uptake DiD. Scale bar represents 20  $\mu m$ . (n = 3-8), \*\*p<0.01 (Pearson's chi-squared test).

**Figure S9**

**Supplementary Figure S9 – AT3q130 animals show normal pharyngeal pumping rate.** In *C. elegans*, drug availability through ingestion can be dependent on the contractions (pumping) of the pharynx. Since WT and AT3q130 animals have similar pharyngeal pumping rates, this suggests no differential drug entry through the ingestion route. (n = 31-32;  $\pm$  SD) (Independent samples non parametric Mann-Whitney test).

**Figure S10**

**Supplementary Figure S10 (related with Figure 5) – DOP-1 is dispensable for aripiprazole beneficial effect on mutant ATXN3 animals.** Even though aripiprazole effect is not classically attributed to DRD<sub>1</sub> targeting, the *C. elegans* DRD<sub>1</sub> ortholog, DOP-1, presented recognizable similarity to DRD<sub>2</sub> (38.15%). To exclude some promiscuity of compound binding to receptors, we also tested the  $\Delta$ dop-1; AT3q130 double mutant and verified that upon ablation of *dop-1*, aripiprazole is still able to improve AT3q130 animals motor phenotype. (n = 8,  $\pm$  SD), \*\*p<0.01 (Factorial ANOVA, followed by a Sidak test corrected for BCA for multiple comparisons).

### 1.3 Supplementary Tables

**Supplementary Table S1.** Descriptive statistics regarding locomotion defects of AT3q130 animals treated with aripiprazole. Means of the locomotion defective phenotype (with the respective standard error) are reported for all tested concentrations of aripiprazole. Comparisons between each concentration were carried out using Factorial ANOVA, followed by a Sidak test corrected for BCA for multiple comparisons. Efficiency was assessed using the following formula: Efficiency (%) =  $\frac{\text{AT3q130 DMSO} - \text{AT3q130 drug}}{\text{AT3q130 DMSO} - \text{WT}}$ . Effect size was given by Cohen's  $d = \frac{\text{Mean DMSO} - \text{Mean drug}}{\text{Pooled SD}}$ .

Strain	Concentration (μM)	Mean locomotion defective ±SD (n)	Group comparison (n) Mean locomotion defective ±SD	P-value	Efficiency (%)	Effect Size
AT3q130	0	44.6±3.1	WT 14.8±3.2	$p=0.001$		
	0.001	40.6±4.4	mATXN3 44.6±3.1	$p=0.117$	14%	1.5
	0.01	34.5±3.1	mATXN3 44.6±3.1	$p=0.001$	34%	4.6
	0.1	32.3±3.8	mATXN3 44.6±3.1	$p=0.001$	41%	5.0
	1	24.9±3.2	mATXN3 44.6±3.1	$p=0.001$	66%	8.8
	10	23.6±3.6	mATXN3 44.6±3.1	$p=0.001$	71%	8.9
	50	31.4±2.8	mATXN3 44.6±3.1	$p=0.001$	44%	6.4

**Supplementary Table S2.** Descriptive survival statistics of AT3q130 animals treated with 10  $\mu$ M aripiprazole. The median and mean (with the respective standard error) are reported for all variables. Comparisons between each condition were carried out using a Cox regression model, with the p-value, Hazard Ratio and respective 95% confidence interval being reported.

<b>Condition</b>	<b>Median Lifespan (s.e.m.)</b>	<b>Mean Lifespan (s.e.m.)</b>	<b>Control Condition</b>	<b>Median Lifespan (s.e.m.)</b>	<b>Mean Lifespan (s.e.m.)</b>	<b>p-value (Cox)</b>	<b>Hazard Ratio (95% CI)</b>
<b>N2 + APZ</b>	<b>15 (0.415)</b>	<b>15.386 (0.333)</b>	<b>N2 + DMSO</b>	<b>14 (0.298)</b>	<b>15.105 (0.284)</b>	<b>0.456</b>	<b>0.919 [0.735; 1.149]</b>
<b>AT3Q130 + DMSO</b>	<b>14 (0.347)</b>	<b>15.093 (0.359)</b>	<b>N2 + DMSO</b>	<b>14 (0.298)</b>	<b>15.105 (0.284)</b>	<b>0.662</b>	<b>0.951 [0.761; 1.190]</b>
<b>AT3Q130 + APZ</b>	<b>17 (0.498)</b>	<b>16.465 (0.343)</b>	<b>N2 + DMSO</b>	<b>14 (0.298)</b>	<b>15.105 (0.284)</b>	<b>0.010</b>	<b>0.748 [0.600; 0.933]</b>
<b><i>daf-2</i></b>	<b>29 (1.849)</b>	<b>28.560 (0.848)</b>	<b>N2 + DMSO</b>	<b>14 (0.298)</b>	<b>15.105 (0.284)</b>	<b>&lt; 0.001</b>	<b>0.129 [0.092; 0.181]</b>
<b><i>daf-16</i></b>	<b>12 (0.310)</b>	<b>12.934 (0.223)</b>	<b>N2 + DMSO</b>	<b>14 (0.298)</b>	<b>15.105 (0.284)</b>	<b>&lt; 0.001</b>	<b>1.759 [1.412; 2.190]</b>
<b>AT3Q130 + APZ</b>	<b>17 (0.498)</b>	<b>16.465 (0.343)</b>	<b>AT3Q130 + DMSO</b>	<b>14 (0.347)</b>	<b>15.093 (0.359)</b>	<b>0.031</b>	<b>0.786 [0.632; 0.978]</b>
<b>AT3Q130 + APZ</b>	<b>17 (0.498)</b>	<b>16.465 (0.343)</b>	<b>N2 + APZ</b>	<b>15 (0.415)</b>	<b>15.386 (0.333)</b>	<b>0.066</b>	<b>0.814 [0.654; 1.014]</b>

**Supplementary Table S3 - List of strains used in this study**

Strain ID	Short notation	Genotype	Reference
N2 (Bristol)	Wild type (WT)		(Brenner, 1974)
MAC037/ AM520	AT3q75 (ATXN3 WT)	<i>rmls238</i> [ <i>P<sub>rgef-1</sub></i> ::AT3v1-1q75::yfp]	(Teixeira-Castro et al., 2011)
MAC001/ AM685	AT3q130 (ATXN3 mutant)	<i>rmls263</i> [ <i>P<sub>rgef-1</sub></i> ::AT3v1-1q130::yfp] II	(Teixeira-Castro et al., 2011)
LX702	$\Delta dop-2$	<i>dop-2(vs105)</i> V	(Chase et al., 2004)
MAC222	$\Delta dop-2$ ; AT3q130	<i>dop-2(vs105)</i> V; <i>rmls263</i> [ <i>P<sub>rgef-1</sub></i> ::AT3v1-1q130::yfp] II	(Pereira-Sousa et al., 2021)
LX703	$\Delta dop-3$	<i>dop-3(vs106)</i> X	(Chase et al., 2004)
MAC368	$\Delta dop-3$ ; AT3q130	<i>rmls263</i> [ <i>P<sub>rgef-1</sub></i> ::AT3v1-1q130::yfp] II; <i>dop-3(vs106)</i> X	<b>This study</b>
DA1814	$\Delta ser-1$	<i>ser-1(ok345)</i> X	(Hamdan et al., 1999; Carnell, 2005)
MAC075	$\Delta ser-1$ ; AT3q130	<i>ser-1(ok345)</i> X; <i>rmls263</i> [ <i>P<sub>rgef-1</sub></i> ::AT3v1-1q130::yfp]	(Pereira-Sousa et al., 2021)
AQ866	$\Delta ser-4$	<i>ser-4(ok512)</i> III	(Olde and McCombie, 1997; Carre-Pierrat et al., 2006)
MAC072	$\Delta ser-4$ ; AT3q130	<i>ser-4(ok512)</i> III; <i>rmls263</i> [ <i>P<sub>rgef-1</sub></i> ::AT3v1-1q130::yfp] II	(Teixeira-Castro et al., 2015)
LX636	$\Delta dop-1$	<i>dop-1(vs101)</i> X	(Chase et al., 2004)
MAC171	$\Delta dop-1$ ; AT3q130	<i>dop-1(vs101)</i> X; <i>rmls263</i> [ <i>P<sub>rgef-1</sub></i> ::AT3v1-1q130::yfp] II	(Pereira-Sousa et al., 2021)
tm2654	$\Delta ser-5$	<i>ser-5(tm2654)</i> I	(Hapiak et al., 2009)
MAC013	$\Delta ser-5$ ; AT3q130	<i>ser-5(tm2654)</i> I; <i>rmls263</i> [ <i>P<sub>rgef-1</sub></i> ::AT3v1-1q130::yfp] II	(Pereira-Sousa et al., 2021)
DA2100	$\Delta ser-7$	<i>ser-7(tm1325)</i> X	(Hobson et al., 2006)
MAC017	$\Delta ser-7$ ; AT3q130	<i>rmls263</i> [ <i>P<sub>rgef-1</sub></i> ::AT3v1-1q130::yfp] II; <i>ser-7(tm1325)</i> X	(Pereira-Sousa et al., 2021)
CB1370	$\Delta daf-2$	<i>daf-2(e1370)</i> III	(Kimura et al., 1997)
CF1038	$\Delta daf-16$	<i>daf-16(mu86)</i> I	(Lin et al., 1997)
CB6598	<i>bus-19(e2966)</i>	<i>bus-19(e2966)</i> V	(Yook and Hodgkin, 2007)
PR811	<i>osm-6(p811)</i>	<i>osm-6(p811)</i> V	(Perkins et al., 1986)
JT11069	$\Delta xbx-1$	<i>xbx-1(ok279)</i> V	(Schafer et al., 2003)

**Supplementary Table S4 - List of primers used in this study.**

Gene	Primer	Sequence (5' – 3')
<i>dop-2</i>	dop-2_for1	ACGATTCCTTGCGATTCTGG
	dop-2_rev1	CACAGCCAGGCCTAGGATAA
	dop-2_rev2	GGAGCCTATGCTGCTATGGA
<i>dop-3</i>	dop-3_vs106_F1	TCAAACACATCAGCTGCCCA
	dop-3_vs106_R1	CCTGGCAATGTCTGGGTAGAA
	dop-3_vs106_R2	AGCATATTTGTGACGGTTTGTAGA
<i>ser-4</i>	ser-4for1	TGGAGGGTTCTGGAAAAATG
	ser-4rev1	TGCCGAAAAGAAAAATGGAC
	ser-4rev2	CGAAAACCGAAAAATCTCCA
<i>ser-1</i>	ser-1_for1	GCTGACCCCAACCGTTAATA
	ser-1_rev1	AATCCCAGCAATTGTTTTGC
	ser-1_rev2	AACTCCGATGCAAAATGTGA
<i>dop-1</i>	dop-1_for1	TGTGCTGAAATGAACGAATGA
	dop-1_rev1	GGATTGGCAGAAGAGTTTGC
	dop-1_rev2	CGGAATGGTTTCCTCGTTAT
<i>ser-5</i>	ser-5 F1	CTTCGTCGATTTTGCTCACA
	ser-5 rev 3	TGCGCCAGTAAAGTGTTAATGT
	ser-5 R2	CCAACCAACTTGCTACATCG
<i>ser-7</i>	ser-7_for1	TGGATCTGCTAGCACTGTGG
	ser-7_rev1	CCGGAGATCCTAAGGTAGGC
	ser-7_rev2	ACCCCATTTTGGGCCTATAC

**Supplementary Table S5 – Statistical report.** Effect size was calculated using <https://effect-size-calculator.herokuapp.com/> and [https://www.psychometrica.de/effect\\_size.html](https://www.psychometrica.de/effect_size.html).

Figure		Statistical report	Sample size (n)
Fig. 1A		$F(32, 36) = 2.518; p = 0.0040; \omega^2p = 0.413$	5
Fig. 1B		$F(9, 25.186) = 26.348, p < 0.001, \omega^2p = 0.866$	5
Fig. 1C		$F(3, 8) = 1.414; p = 0.308; \omega^2p = 0.094$	3
Fig. 1D		$F(3, 8) = 1.143; p = 0.389; \omega^2p = 0.034$	3
Fig. 2B	Total area	$t(58) = 0.9583, p = 0.3419, g = 0.245$	28-32
	Number of aggregates	$t(56) = 1.186, p = 0.2404, g = -0.308$	27-31
	Area aggregates	$t(55) = 0.8746, p = 0.3856, g = -0.229$	26-31
Fig. 2D		$t(5,985) = 0.5101, p = 0.6282, g = -0.272$	6
Fig. 2F	Soluble	$t(2) = 0.8012, p = 0.5071, d = 0.462$	3
	SDS-sol	$t(3) = 3.119, p = 0.0525, d = -1.560$	4
	SDS-res	$t(2) = 1.317, p = 0.3186, d = 0.760$	4
Fig. 2H		$t(21) = -0.741, p = 0.467, g = -1.012$	11-12
Fig. 4A		$F(7, 10.492) = 33.985, p < 0.001, \omega^2p = 0.926$	4
Fig. 4B		$F(7, 15.949) = 54.976, p < 0.001, \omega^2p = 0.940$	4
Fig. 4C		$F(9, 30) = 12.532, p < 0.001, \omega^2p = 0.722$	4
Fig. 4D		$F(9, 12.527) = 9.936; p < 0.001; \omega^2p = 0.782$	4
Fig. 4E		$F(9, 29) = 30.125; p < 0.001; \omega^2p = 0.871$	4
Fig. 4F		$F(7, 24) = 39.316, p < 0.001, \omega^2p = 0.893$	4
Fig. 4G		$F(13, 42) = 5.592, p < 0.0001, \omega^2p = 0.516$	4
Fig. 4H		$F(11, 24) = 6.333, p < 0.001, \omega^2p = 0.620$	3
Fig. 5A		$F(10, 20.961) = 32.870, p < 0.001, \omega^2p = 0.909$	5



Fig. 5B	$F(10, 33) = 28.775, p < 0.001, \omega^2p = 0.863$	4
Fig. 5C	$F(9, 20) = 15.70: p < 0.001, \omega^2p = 0.815$	3
Fig. 5D	$F(9, 30) = 9.827: p < 0.001; \omega^2p = 0.665$	4
Fig. S1 D	$F(2.000, 3.736) = 14.27; p = 0.0178; \omega^2p = 0.798$	4
Fig. S2	$F(18, 22.497) = 11.769, p < 0.001, \omega^2p = 0.712$	3
Fig. S7	$F(7,47) = 31.390, p<0.001, \omega^2p = 0.795$	6-8
Fig. S8	$X^2(8) = 42.000, p<0.001, V = 18.330$	3-8
Fig. S9	$U(31, 32) = 354.000, p=0.061, \eta^2 = 0.06$	31-32
Fig. S10	$F(7, 23.831) = 17.982, p < 0.001, \omega^2p = 0.789$	8

## 1.4 Supplementary References

- Brenner, S. (1974). The genetics of *Caenorhabditis elegans*. *Genetics* 77(1), 71-94.
- Carnell, L. (2005). The G-Protein-Coupled Serotonin Receptor SER-1 Regulates Egg Laying and Male Mating Behaviors in *Caenorhabditis elegans*. *Journal of Neuroscience* 25(46), 10671-10681. doi: 10.1523/jneurosci.3399-05.2005.
- Carre-Pierrat, M., Baillie, D., Johnsen, R., Hyde, R., Hart, A., Granger, L., et al. (2006). Characterization of the *Caenorhabditis elegans* G protein-coupled serotonin receptors. *Invertebrate Neuroscience* 6(4), 189-205. doi: 10.1007/s10158-006-0033-z.
- Chase, D.L., Pepper, J.S., and Koelle, M.R. (2004). Mechanism of extrasynaptic dopamine signaling in *Caenorhabditis elegans*. *Nat Neurosci* 7(10), 1096-1103. doi: 10.1038/nn1316.
- Hamdan, F.F., Ungrin, M.D., Abramovitz, M., and Ribeiro, P. (1999). Characterization of a novel serotonin receptor from *Caenorhabditis elegans*: cloning and expression of two splice variants. *J Neurochem* 72(4), 1372-1383. doi: 10.1046/j.1471-4159.1999.721372.x.
- Hapiak, V.M., Hobson, R.J., Hughes, L., Smith, K., Harris, G., Condon, C., et al. (2009). Dual excitatory and inhibitory serotonergic inputs modulate egg laying in *Caenorhabditis elegans*. *Genetics* 181(1), 153-163. doi: 10.1534/genetics.108.096891.
- Hobson, R.J., Hapiak, V.M., Xiao, H., Buehrer, K.L., Komuniecki, P.R., and Komuniecki, R.W. (2006). SER-7, a *Caenorhabditis elegans* 5-HT7-like receptor, is essential for the 5-HT stimulation of pharyngeal pumping and egg laying. *Genetics* 172(1), 159-169. doi: 10.1534/genetics.105.044495.
- Kimura, K.D., Tissenbaum, H.A., Liu, Y., and Ruvkun, G. (1997). daf-2, an insulin receptor-like gene that regulates longevity and diapause in *Caenorhabditis elegans*. *Science* 277(5328), 942-946. doi: 10.1126/science.277.5328.942.
- Lin, K., Dorman, J.B., Rodan, A., and Kenyon, C. (1997). daf-16: An HNF-3/forkhead family member that can function to double the life-span of *Caenorhabditis elegans*. *Science* 278(5341), 1319-1322. doi: 10.1126/science.278.5341.1319.

- Notredame, C., Higgins, D.G., and Heringa, J. (2000). T-Coffee: A novel method for fast and accurate multiple sequence alignment. *J Mol Biol* 302(1), 205-217. doi: 10.1006/jmbi.2000.4042.
- Olde, B., and McCombie, W.R. (1997). Molecular cloning and functional expression of a serotonin receptor from *Caenorhabditis elegans*. *J Mol Neurosci* 8(1), 53-62. doi: 10.1007/BF02736863.
- Pereira-Sousa, J., Ferreira-Lomba, B., Bellver-Sanchis, A., Vilasboas-Campos, D., Fernandes, J.H., Costa, M.D., et al. (2021). Identification of the 5-HT1A serotonin receptor as a novel therapeutic target in a *C. elegans* model of Machado-Joseph disease. *Neurobiology of Disease*, 105278. doi: 10.1016/j.nbd.2021.105278.
- Perkins, L.A., Hedgecock, E.M., Thomson, J.N., and Culotti, J.G. (1986). Mutant sensory cilia in the nematode *Caenorhabditis elegans*. *Dev Biol* 117(2), 456-487. doi: 10.1016/0012-1606(86)90314-3.
- Schafer, J.C., Haycraft, C.J., Thomas, J.H., Yoder, B.K., and Swoboda, P. (2003). XBX-1 encodes a dynein light intermediate chain required for retrograde intraflagellar transport and cilia assembly in *Caenorhabditis elegans*. *Mol Biol Cell* 14(5), 2057-2070. doi: 10.1091/mbc.e02-10-0677.
- Teixeira-Castro, A., Ailion, M., Jalles, A., Brignull, H.R., Vilaca, J.L., Dias, N., et al. (2011). Neuron-specific proteotoxicity of mutant ataxin-3 in *C. elegans*: rescue by the DAF-16 and HSF-1 pathways. *Hum Mol Genet* 20(15), 2996-3009. doi: 10.1093/hmg/ddr203.
- Teixeira-Castro, A., Jalles, A., Esteves, S., Kang, S., da Silva Santos, L., Silva-Fernandes, A., et al. (2015). Serotonergic signalling suppresses ataxin 3 aggregation and neurotoxicity in animal models of Machado-Joseph disease. *Brain* 138(11), 3221-3237. doi: 10.1093/brain/awv262.
- Tong, Y.G., and Burglin, T.R. (2010). Conditions for dye-filling of sensory neurons in *Caenorhabditis elegans*. *J Neurosci Methods* 188(1), 58-61. doi: 10.1016/j.jneumeth.2010.02.003.
- Troshin, P.V., Procter, J.B., and Barton, G.J. (2011). Java bioinformatics analysis web services for multiple sequence alignment--JABAWS:MSA. *Bioinformatics* 27(14), 2001-2002. doi: 10.1093/bioinformatics/btr304.
- Xiong, H., Pears, C., and Woollard, A. (2017). An enhanced *C. elegans* based platform for toxicity assessment. *Sci Rep* 7(1), 9839. doi: 10.1038/s41598-017-10454-3.
- Yook, K., and Hodgkin, J. (2007). Mos1 mutagenesis reveals a diversity of mechanisms affecting response of *Caenorhabditis elegans* to the bacterial pathogen *Microbacterium nematophilum*. *Genetics* 175(2), 681-697. doi: 10.1534/genetics.106.060087.